CSPC Pharmaceutical Group Limited (CSPCY) on Monday said its Tacrolimus Extended-Release Capsules have been approved by China's National Medical Products Administration.
The product is indicated for preventing graft rejection after kidney transplantation, for maintaining graft tolerance after liver transplantation, and for treating kidney or liver transplant rejection that is unresponsive to other immunosuppressive therapies.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.